Related Experiment Videos
[Clinical evaluation of faropenem against infections in pediatric fields]
1Department of Pediatrics, Second Tokyo National Hospital.
Abstract:
The recent increases in the prevalence of penicillin-resistant Streptococcus pneumoniae becomes a point at issue clinically. We carried out a clinical study in 40 cases in the pediatrics department, as faropenem (FRPM) was proved to have an excellent antimicrobial activity against penicillin-resistant Streptococcus pneumoniae. The study was planned to investigate in detail the movement of stools that had been a problem in a clinical development studies out before. In this study, an observation of the daily movement of stools was one of the principal evaluation items, hence the patients were divided into two groups. One group (S-group) were administered FRPM only, the other group (E-group) were administered FRPM in combination with a medicine for intestinal disorders (Enteronon-R). An observed frequencies of any loose bowel movements were 94.7% in S-group, and 63.2% in E-group, hence the study suggested that the combination drug was effective. The patients observed higher frequencies of development of the movement of stools, all of them were recovered from in the course of administration or within 4 days after administration, however whether or not being treated symptomatic therapy. Clinical efficacy rates of FRPM on mainly respiratory infections were 94.6%. In this study, 4 strains (patients) of penicillin-resistant Streptococcus pneumoniae were isolated. Against penicillin-resistant Streptococcus pneumoniae, FRPM demonstrated more potent antibacterial activity than the oral penicillins and cephems tested here except cefditoren. Clinical efficacies was deemed effective in all of the 4 cases, and bacteriologically, 3 organisms were eradicated. As for side effects including diarrhea and loose stool, no serious side effects were observed. Based on the above results, FRPM is effective against most infections in the pediatric field which Streptococcus pneumoniae are isolated at high frequencies highly, and is considered to cases in be useful an attention will have to be paid to stool movement, however.
Insights
Faropenem (FRPM) effectively treats penicillin-resistant Streptococcus pneumoniae infections in children. Combining FRPM with an intestinal medication reduced the incidence of loose stools, a common side effect.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Resistance
- Pharmacology
Background:
- Increasing prevalence of penicillin-resistant Streptococcus pneumoniae poses clinical challenges.
- Faropenem (FRPM) exhibits potent antimicrobial activity against resistant bacterial strains.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of faropenem (FRPM) in pediatric patients.
- To investigate the impact of FRPM on stool movement, a noted side effect in previous studies.
- To assess FRPM's activity against penicillin-resistant Streptococcus pneumoniae.
Main Methods:
- A clinical study involving 40 pediatric patients.
- Patients were divided into two groups: one receiving FRPM alone (S-group), the other receiving FRPM plus an intestinal disorder medication (E-group).
- Daily stool movements were monitored as a primary evaluation item.
Main Results:
- FRPM demonstrated high clinical efficacy (94.6%) against pediatric infections, particularly respiratory ones.
- In vitro, FRPM showed potent activity against penicillin-resistant Streptococcus pneumoniae.
- The combination group (E-group) experienced significantly fewer loose bowel movements (63.2%) compared to the FRPM-only group (94.7%).
- No serious adverse events were observed, with stool abnormalities resolving during or shortly after treatment.
Conclusions:
- Faropenem (FRPM) is effective and well-tolerated for treating pediatric infections caused by Streptococcus pneumoniae.
- Co-administration of an intestinal medication with FRPM can mitigate the side effect of loose stools.
- FRPM is a valuable therapeutic option for pediatric infections, especially those involving penicillin-resistant Streptococcus pneumoniae.